Eledon Pharmaceuticals shares rise 10.57% intraday after two analysts upgrade to 'strong buy' with $8.5 target.

martes, 24 de febrero de 2026, 10:45 am ET1 min de lectura
ELDN--
Eledon Pharmaceuticals surged 10.57% intraday as two analysts upgraded the stock to "Strong Buy" with a $8.50 target price, implying a 255.65% upside. The company, developing tegoprubart for transplant organ protection and ALS treatment, will showcase its R&D progress at the 2026 Guggenheim Emerging Horizons Biotech Summit, enhancing market exposure and investor interest.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios